Si-722 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
226 | Interstitial cystitis with Hunners ulcer | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04208087 (ClinicalTrials.gov) | March 30, 2020 | 25/11/2019 | PK and Safety of SI-722 in IC/BPS | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of SI-722 Intravesical Instillation in Interstitial Cystitis/Bladder Pain Syndrome Subjects | Interstitial Cystitis;Bladder Pain Syndrome | Drug: SI-722;Drug: Placebo | Seikagaku Corporation | NULL | Recruiting | 18 Years | 80 Years | All | 32 | Phase 1;Phase 2 | United States |